USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes
Summary
The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.
What changed
USPTO has published patent application US20260083691A1, filed by Lantern Pharma Inc., detailing a method for treating cancer. The invention involves administering a combination of an acylfulvene and an anti-CD20 antibody, such as rituximab or obinutuzumab, which may be effective against B-cell cancers.
This publication represents a new patent filing and does not impose immediate regulatory obligations on pharmaceutical companies. However, it signifies potential new intellectual property in cancer therapeutics, which may influence future drug development strategies and market exclusivity for companies operating in oncology and B-cell cancer treatment.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATING CANCERS WITH COMBINATIONS OF ANTI-CD20 ANTIBODY AND ACYLFULVENES
Application US20260083691A1 Kind: A1 Mar 26, 2026
Assignee
Lantern Pharma Inc.
Inventors
Jianli Zhou, Kishor Bhatia
Abstract
A method of treating cancer includes administering a combination of active agents comprising a therapeutically effective amount of an acylfulvene, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an anti-CD20 antibody. The anti-CD20 antibody can be selected from rituximab, obinutuzumab, ofatumumab, and tositumomab. The cancer may be a B-cell cancer.
CPC Classifications
A61K 31/17 A61K 31/337 A61K 33/243 A61P 35/00 C07K 16/2887 A61K 2039/505 A61K 2039/545
Filing Date
2025-12-01
Application No.
19405201
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.